Clinical Trials Browser

Phase 1/2 × Mesothelioma × spartalizumab × Clear all

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1/2 Completed

490 enrolled 77 charts

DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma